抗新型冠状病毒中和抗体药物临床研究进展

Clinical progress of neutralizing antibodies against SARS-CoV-2

摘要:

自1998年预防呼吸合胞病毒的帕利珠单抗药物上市以来，多种靶向病毒的治疗性抗体药物已成功用于感染性疾病的临床治疗。新型冠状病毒肺炎疫情暴发后，多种中和抗体药物快速进入临床研究阶段，展现出积极的治疗及预防效果，并以紧急使用授权的方式用于疫情防控。本文对抗新型冠状病毒中和抗体药物的临床进展和主要临床试验结果进行总结，以期为包括新型冠状病毒肺炎在内的新发、突发传染病中和抗体药物研发提供参考。

Abstract:

Since the palivizumab for respiratory syncytial virus was approved in 1998, therapeutic antibodies against infectious diseases have been widely used in clinical treatment. Since the outbreak of COVID-19, plenty of neutralizing antibodies were developed and transferred into clinical trials, holding enormous promise for the treatment of COVID-19 under the context of emergency use authorization. This review summarizes the clinical progress of these drugs, in order to provide a reference for the research and development of neutralizing antibody drugs for the future.